258 related articles for article (PubMed ID: 22406481)
1. Utility of p63 and high molecular weight cytokeratin in the distinction between urothelial carcinoma with prostatic stromal invasion and urothelial carcinoma with colonisation of prostatic ducts and acini.
Chastain EC; Oliva IV; Osunkoya AO
Pathology; 2012 Apr; 44(3):199-203. PubMed ID: 22406481
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells.
Weinstein MH; Signoretti S; Loda M
Mod Pathol; 2002 Dec; 15(12):1302-8. PubMed ID: 12481011
[TBL] [Abstract][Full Text] [Related]
3. Urothelial carcinoma of the bladder with transmural and direct prostatic stromal invasion: does extent of stromal invasion significantly impact patient outcome?
Oliva IV; Smith SL; Chen Z; Osunkoya AO
Hum Pathol; 2011 Jan; 42(1):51-6. PubMed ID: 20870265
[TBL] [Abstract][Full Text] [Related]
4. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
5. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
6. False positive labeling of prostate cancer with high molecular weight cytokeratin: p63 a more specific immunomarker for basal cells.
Ali TZ; Epstein JI
Am J Surg Pathol; 2008 Dec; 32(12):1890-5. PubMed ID: 18813120
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
8. p63 as a complimentary basal cell specific marker to high molecular weight-cytokeratin in distinguishing prostatic carcinoma from benign prostatic lesions.
Shiran MS; Tan GC; Sabariah AR; Rampal L; Phang KS
Med J Malaysia; 2007 Mar; 62(1):36-9. PubMed ID: 17682568
[TBL] [Abstract][Full Text] [Related]
9. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma.
Kunju LP; Mehra R; Snyder M; Shah RB
Am J Clin Pathol; 2006 May; 125(5):675-81. PubMed ID: 16707367
[TBL] [Abstract][Full Text] [Related]
10. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
11. Double cocktail immunostains with high molecular weight cytokeratin and GATA-3: useful stain to discriminate in situ involvement of prostatic ducts or acini from stromal invasion by urothelial carcinoma in the prostate.
Lee J; Yoo Y; Park S; Cho MS; Sung SH; Ro JY
J Pathol Transl Med; 2020 Mar; 54(2):146-153. PubMed ID: 32028755
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical antibody cocktail staining (p63/HMWCK/AMACR) of ductal adenocarcinoma and Gleason pattern 4 cribriform and noncribriform acinar adenocarcinomas of the prostate.
Herawi M; Epstein JI
Am J Surg Pathol; 2007 Jun; 31(6):889-94. PubMed ID: 17527076
[TBL] [Abstract][Full Text] [Related]
13. Invasive urothelial carcinoma with chordoid features: a report of 12 distinct cases characterized by prominent myxoid stroma and cordlike epithelial architecture.
Cox RM; Schneider AG; Sangoi AR; Clingan WJ; Gokden N; McKenney JK
Am J Surg Pathol; 2009 Aug; 33(8):1213-9. PubMed ID: 19542871
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic utility of androgen receptor expression in discriminating poorly differentiated urothelial and prostate carcinoma.
Downes MR; Torlakovic EE; Aldaoud N; Zlotta AR; Evans AJ; van der Kwast TH
J Clin Pathol; 2013 Sep; 66(9):779-86. PubMed ID: 23775437
[TBL] [Abstract][Full Text] [Related]
15. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
16. Immunoreactivity of p63 in monolayered and in vitro stratified human urothelial cell cultures compared with native urothelial tissue.
Feil G; Maurer S; Nagele U; Krug J; Bock C; Sievert KD; Stenzl A
Eur Urol; 2008 May; 53(5):1066-72. PubMed ID: 17980954
[TBL] [Abstract][Full Text] [Related]
17. Basal cell cocktail (34betaE12 + p63) improves the detection of prostate basal cells.
Zhou M; Shah R; Shen R; Rubin MA
Am J Surg Pathol; 2003 Mar; 27(3):365-71. PubMed ID: 12604893
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer with aberrant diffuse p63 expression: report of a case and review of the literature and morphologic mimics.
Wu A; Kunju LP
Arch Pathol Lab Med; 2013 Sep; 137(9):1179-84. PubMed ID: 23991727
[TBL] [Abstract][Full Text] [Related]
19. Coordinate expression of cytokeratins 7 and 20 in prostate adenocarcinoma and bladder urothelial carcinoma.
Bassily NH; Vallorosi CJ; Akdas G; Montie JE; Rubin MA
Am J Clin Pathol; 2000 Mar; 113(3):383-8. PubMed ID: 10705819
[TBL] [Abstract][Full Text] [Related]
20. Validation of new AJCC exclusion criteria for subepithelial prostatic stromal invasion from pT4a bladder urothelial carcinoma.
Patel AR; Cohn JA; Abd El Latif A; Miocinovic R; Steinberg GD; Paner GP; Hansel DE
J Urol; 2013 Jan; 189(1):53-8. PubMed ID: 23164389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]